For Chronic Lymphocytic Lymphoma (CLL) and Mantle Cell Lymphoma (MCL), Ibrutinib Plus ABT-199 May Be Effective
the Cancer Therapy Advisor take:
According to findings presented at the American Association for Cancer Research special conference Hematologic Malignancies: Translating Discoveries to Novel Therapies in Philadelphia, Pennsylvania, ibrutinib in combination with ABT-199 may be effective for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
In this study, researchers from the University of Virginia School of Medicine in Charlottesville, Virginia, tested ibrutinib in combination with ABT-199 in blood samples from 16 patients with either MCL or CLL. They found that 23% of cells treated with the combination underwent apoptosis while only 3.8% and 3% of cells treated with ibrutinib and ABT-199, respectively, underwent apoptosis. Researchers also found that the combination of ibrutinib and ABT-199 synergistically killed cancer cells in patients with CLL.
Ibrutinib (Imbruvica), a tyrosine kinase inhibitor, was recently approved by the U.S. Food and Drug Administration for the treatment of patients with MCL and CLL. ABT-199 is an investigational, selective B-cell lymphoma 2 (Bcl-2) inhibitor being studied for the treatment of patients with B-cell lymphomas, including MCL and CLL.
Ibrutinib in combination with ABT-199 may be effective for MCL and CLL.
Using the molecularly targeted drug ibrutinib (Imbruvica) together with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), according to preclinical data presented at the American Association for Cancer Research special conference, Hematologic Malignancies: Translating Discoveries to Novel Therapies, held Sept. 20-23.
"Ibrutinib was recently approved by the FDA [U.S. Food and Drug Administration] for the treatment of both mantle cell lymphoma and chronic lymphocytic leukemia," said Michael J. Weber, PhD, professor of microbiology, immunology, and cancer biology at the University of Virginia School of Medicine in Charlottesville.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma